Table 2.
Clinical Outcomes in UDCA‐Treated Patients Based on Phenotype
|
Portal Hypertensive Complications (5 Years) |
Biliary Complications (5 Years) |
Survival With Native Liver (5 Years) |
Event‐Free Survival (5 Years) |
|
|---|---|---|---|---|
| PSC without IBD |
30% (95% CI 15‐33) |
10% (95% CI 3‐29) |
81% (95% CI 48‐94) |
66% (95% CI 41‐82) |
| PSC‐IBD |
20% (95% CI 14‐27) |
6% (95% CI 3‐11) |
89% (95% CI 81‐93) |
80% (95% CI 72‐85) |
| Pvalue | 0.460 | 0.541 | 0.849 | 0.186 |
| PSC without AIH |
24% (95% CI 17‐33) |
8% (95% CI 4‐15) |
85% (95% CI 74‐91) |
74% (95% CI 64‐81) |
| PSC + AIH |
16% (95% CI 9‐28) |
4% (95% CI 1‐12) |
94% (95% CI 84‐98) |
84% (95% CI 72‐91) |
| Pvalue | 0.203 | 0.348 | 0.175 | 0.074 |
| Small‐duct PSC |
19% (95% CI 10‐34) |
0% (95% CI 0‐0) |
85% (95% CI 65‐94) |
82% (95% CI 65‐91) |
| Large‐duct PSC |
22% (95% CI 16‐30) |
8% (95% CI 5‐15) |
89% (95% CI 80‐94) |
76% (95% CI 67‐83) |
| Pvalue | 0.933 | * | 0.788 | 0.235 |
Abbreviation: CI, confidence interval.
By definition, patients with small‐duct PSC could not have cholangiographic abnormalities, so a statistical comparison is not listed.